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Abstract 
Objective: The current study was designed to compare global gene expression profiles of 
subcutaneous adipose tissue (SCAT) from obese and non-obese young men using whole 
human genome microarrays. 
Research methods and procedures: Sixteen healthy young men aged 20-27 participated 
in the study. Total RNA was isolated from SCAT, and competitively hybridized with a 
universal human reference RNA to Agilent's 44K whole human genome chip. A paired 
study design was used; ratios for each obese individual were directly compared to those 
of a matched non-obese individual. 
Results and Discussion: We identified 114 significantly up-regulated and 204 down-
regulated genes and transcripts in obese SCAT, 232 of which have defined names. For 
181 of the genes with defined names, adipose tissue expression has not been reported 
previously. Gene Ontology (GO) analysis revealed an over-representation of genes 
involved in apoptosis, cell adhesion, cellular morphogenesis, and cell growth as up 
regulated in obese subjects. Genes with functions in the mitochondria, including genes 
involved in A TP coupled electron transport, were down regulated in obese subjects. 
Clustering analysis identified a sub-set of 27 genes that was able to accurately distinguish 
obese from non-obese subjects. Moreover, numerous genes that may influence the rate of 
lipolysis were also found to be differentially expressed. 
Key Words: adiposity, whole human genome microarrays, cluster analysis, lipolysis. 
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Chapter 1: Introduction 
Chapter 1.1: Introduction to obesity 
Obesity is quickly becoming one of the major health concerns in the developed 
world. Between 1985 and 2001, the number of overweight Canadian women increased by 
32%, while the incidence of obesity doubled (Health Canada report, 2003). This trend 
was even more evident in men, where the number of overweight individuals rose by 41% 
and the incidence of obesity almost tripled (Health Canada report, 2003). This has put an 
enormous strain on the Canadian health care system. It has been calculated that in 2001 
alone, 5.3 billion dollars was spent treating the consequences of obesity, accounting for 
2.2 % of all Canadian healthcare costs (Katzmarzyk eta/., 2004). 
Once thought to be a condition of behavior, that is, too much food intake and not 
enough exercise, obesity is now recognized as a chronic disease with molecular causes. 
This change in point of view has spurred a wave of research into the genes that may 
cause or predispose an individual to obesity and associated complications such as insulin 
resistance and type 2 diabetes. Defining genes that contribute to obesity has provided 
many problems for researchers. Obesity can result from single gene mutations, such as 
those in the leptin gene (Montague et al., 1997) and the melanocortin-4 receptor gene 
(Lubrano-Berthelier et al., 2004), but they are extremely rare in the population (Snyder et 
al., 2004). Only 173 human obesity cases due to single gene mutations in ten different 
genes have been reported (Perusse et a/., 2005). The common form of obesity is thought 
to be a complex disease, and results from the combined effects of many genes and 
environmental factors. In this model, many genes can have a small influence on the status 
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of adiposity in a given individual or predispose an individual to becoming obese, and the 
effect of these genes can be influenced by environmental factors. 
To further complicate the study of obesity, many other disorders tend to be 
common in individuals who are obese, and these disorders may have separate or 
overlapping genetic causes or predispositions. Insulin resistance is common in obese 
individuals, and can lead to numerous complications such as the metabolic syndrome and 
type 2 diabetes. The .metabolic syndrome is collection of metabolic abnormalities that 
include glucose intolerance, insulin resistance, central obesity, dyslipidaemia, and 
hypertension (Eckel et a/., 2005). The above are all risk factors for the development of 
cardiovascular disease, a condition that is also common in obese individuals. Insulin 
resistance and obesity are also the primary risk factors for the development of type two 
diabetes. A strong correlation between obesity, defined by body mass index (BMI), and 
the relative risk for diabetes has been shown in both men (Chan eta/., 1994) and women 
(Colditz eta/., 1995) (Figure 1). The study of the genetic control of obesity and related 
metabolic disorders will thus help in the understanding and treatment of individuals who 
may be predisposed to develop these conditions. 
Chapter 1.2: Adipose tissue and its active role in the etiology of obesity 
Adipose tissue has long been considered a passive, inactive tissue simply present 
for the storage of triglycerides (Kim et a/., 2000). However the discovery of numerous 
endocrine, paracrine and autocrine functions have shed new light on adipose tissue, and 
the active role it may play in the development of obesity and related metabolic disorders 
(Mohamed-Ali eta/., 1998). A number of factors are known to be predominately 
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Figure 1: Age adjusted risk of developing type 2 diabetes according to body mass index. 
Adapted from (Sharma, 2003), original data from (Chan et al., 1994 and Colditz et al., 
1995). 
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expressed and secreted by adipose tissue (Table 1}, allowing for communication between 
adipose tissue and other tissues and organs. Thus the study of obesity has, to a large 
degree, become the study of adipose tissue. Defining how adipose tissue works on the 
genetic level and how it functions differently in lean and obese individuals will provide 
obesity candidate genes that may act as targets for the development of obesity related 
drugs. 
The use of animal models has greatly increased our knowledge about how adipose 
tissue functions, and how important it is to maintain a healthy level of adipose tissue. 
Moitra and associates (1998) created a transgenic mouse that lacks adipose tissue. These 
mice express a dominant-negative protein, termed A-ZIP/F, under the control of the 
adipose-specific aP2 enhancer/promoter. A-ZIP/FF mice were diabetic, had elevated 
serum glucose, insulin, free fatty acids and triglycerides (TG}. Furthermore, the mice had 
reduced fecundity and premature death. In humans, mutations in genes such as 1-
acylglycerol-3-phosphate 0-acyltransferase 2 (AGPAT2) cause a similar phenotype, as 
these individuals have reduced fat, or a complete lack of fat tissue. Similar to the mouse 
model, these individuals have early onset diabetes, hypertriglyceridema, and severe 
insulin resistance (Simha et a/., 2003). Thus, the profound effects of lacking adipose 
tissue reiterates its importance in maintaining energy homeostasis and the overall health 
of the body. 
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Table 1: Proteins that are predominately expressed and/or secreted from adipose 
tissue that have been implicated in the pathophysiology of obesity. 
Proteins released Omental fat Sub-cutaneous fat 
Lipoprotein lipase + + 
Acylation stimulating protein + ++ 
Cholesterol-ester transfer protein ++ + 
Retinol binding protein + + 
Plasminogen activator inhibitor-! ++ + 
Estrogens + + 
Leptin + ++ 
Angiotensinogen ++ + 
Adiponectin ++ + 
Tumor necrosis factor a + + 
Interleukin-6 ++ + 
Insulin-like growth factor-1 + + 
Insulin-like growth factor binding protein-3 + + 
Monobutyrin + + 
Peroxisomal proliferators activated + ++ 
receptor-y 
Uncoupling protein-1 + ++ 
Uncoupling protein-2 + ++ 
++ indicates increase expression when compared to the other fat deposit. 
Adapted from (Wajchenberg, 2000). 
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1.3: Overview of lipolysis 
Lipolysis is arguably one of the most important processes that occurs in adipose 
tissue. This involves the break down of triglycerides in the lipid storage droplet, and the 
subsequent release of free fatty acids and glycerol. Catecholamines are powerful 
regulators of lipolysis in human adipocytes through stimulatory ~ 1 and ~2 
adrenoreceptors and inhibitory a2 adrenoreceptors (Fain et al., 1983). A third ~ 
adrenoreceptor (~3) can also stimulate lipolysis, but is only active in the omental fat 
deposit. On the other hand, lipolysis can be inhibited in human adipocytes through the 
inhibitory action of the insulin receptor (reviewed by Large et al., 1998) and the 
adenosine receptor (Schoelch et al., 2004). Lipolysis may also be inhibited by the AMP 
activated protein kinase (AMPK) in human adipocytes (Winder et al., 1999). 
The stimulatory action of catecholamines induces lipolysis through the second 
messenger cAMP. This molecule activates the cAMP dependant protein kinase, otherwise 
know as protein kinase A (PKA). The PKA holoenzyme is a tetramer consisting of two 
regulatory and two catalytic subunits. In mice, at least four isoforms of the regulatory 
subunit are transcribed (Ria, RI~, Rlla., and RII~), and two isoforms of the catalytic 
subunit are transcribed (Ca. and C~) (Planas et al., 1999). Binding of cAMP causes the 
dissociation of the regulatory subunits, allowing free catalytic subunits to phosphorylate 
downstream targets. Different isoforms of the regulatory subunits have tissue specific 
patterns of expression, leading to the belief that isoform diversity confers at least some 
specificity by assembling different holoenzyme complexes in different tissues or different 
parts of the cell (Planas et al., 1999). With respect to lipolysis, the RII~ subunit may be 
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of importance as it is the most abundant subunit expressed in the adipose tissue and has 
limited expression elsewhere (Planas et a/., 1999). 
Upon activation by cAMP, PK.A can phosphorylate hormone sensitive lipase 
(HSL) at three distinct sites: serine 563, 659, and 660 (reviewed by Holm, 2003), which 
leads to activation and translocation to the surface of the lipid storage droplet. HSL plays 
a crucial role in the hydrolysis of triacylglycerol and cholesteryl esters in various tissues 
including adipose tissues (Sekiya eta/., 2004). PK.A can also phosphorylate perilipin, a 
protein that acts as a barrier to protect the lipid droplet from HSL. Phosphorylation by 
PK.A causes perilipin to translocate away from the lipid droplet (Zhang et al., 2003), 
allowing HSL access to the stored triglycerides. In opposition to this process, AMPK can 
phosphorylate HSL at a fourth site (serine 565) and this is believed to inhibit PK.A's 
ability to phosphorylate and activate HSL (Holm et a/., 2003). The process of lipolysis 
may also be inhibited through the actions of insulin and insulin-like growth factors 
(IGFs). Binding of insulin and other related growth factors to their receptors has an 
inhibitory effect on the concentration of cAMP (Holm, 2003), leading to less activation 
of PK.A and thus less activated HSL and perilipin. An overview of the lipolytic pathway 
is seen in Figure 2. 
In vitro studies have shown that alterations in the sensitivity of lipolytic induction 
may contribute to obesity. For example, variations in the DNA sequence of beta 
adrenoreceptors have been shown to affect function and their ability to induce lipolysis, 
and these variations also associate with obesity (reviewed by Amer, 2001 ). Furthermore, 
genes involved in lipolytic induction such as the natriuetic peptide receptor 3 (NPR3) and 
the adrenergic f32 receptor (ADRB2), were found to have decreased expression in human 
7 
Insulin-R 
LPD 
Figure 2: Overview of the lipolytic pathway. Stimulation via a or ~ adrenoreceptors 
causes accumulation of cAMP, which binds and activates protein kinase A (PKA). PKA 
can then phosphorylate perilipin causing it to translocate away from the lipid storage 
droplet (LPD). Activated PKA can also phosphorylate hormone sensitive lipase at three 
sites, causing activation of HSL, and subsequent hydroloysis of trigylcerides (TG), 
forming glycerol and non-esterified fatty acids (NEFA). Signaling via the insulin receptor 
inhibits this process via lowering cAMP levels. The AMP activated protein kinase 
(AMPK) can also phosphorylate HSL at a fourth residue, presumably blocking 
phosphorylation and/or activation by PKA. 
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visceral adipose tissue from obese males, while genes that inhibit lipolysis, such as the 
neuropeptide Y receptor (NPYR) and the adrenergic 13 receptor kinase 2 (ADRBK2) have 
increased expression (Gomez-Ambrosi et a/., 2004). The study of animal models also 
adds strength to this observation. Rllj3 knockout mice (knock out of the principle 
regulatory PKA subunit) are lean, resistant to diet induced obesity, and have a blunted 
capacity for catecholamine induced lipolysis (Planas et a/., 1999). Since obesity may 
result from a reduced rate oflipolysis, thereby allowing for the excessive accumulation of 
triglyceride in the lipid storage droplet, interventions that increase the rate of lipolysis 
may represent a means of treatment for obesity. 
Chapter 1.4: Energy charge and the mitochondrial involvement with obesity 
It has long been believed that the production of A TP within the mitochondria of 
adipocytes can affect the accumulation or release of body fat stores (Rossmeisl et a/., 
2004). Supporting evidence for this theory was gained by the generation of transgenic 
mice that ectopically express uncoupling proteins, which reduce the amount of A TP 
produced in the mitochondria by uncoupling A TP synthesis from electron transport. 
Ectopic expression of uncoupling protein 1 in the white adipose tissue of mice results in 
less A TP production as well as protection from dietary and genetic induced obesity 
(Rossmeisl eta/.. 2004). Similarly, levels ofUCP in brown adipose tissue were found to 
be lower in obese humans when compared to lean controls (Oberkofler et a/., 1997), 
which is consistent with reduced energy expenditure in obese individuals. However it 
remains to be determined if reduced expression of uncoupling proteins plays a significant 
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role in the pathogenesis of obesity as brown adipose tissue accounts for only a small 
percent of adipose tissue in adults. 
In order for energy production m the mitochondria to be involved in the 
pathophysiology of obesity, there must be a link between cellular A TP concentration and 
the rate of lipolysis and/or lipogenesis. This link may be provided through the actions of 
AMPK. This enzyme responds to changes in the AMP/ATP ratio. A decrease in cellular 
A TP concentration activates this enzyme which can then proceed to stimulate processes 
that produce A TP, while inhibiting processes that consume A TP (reviewed by Hardie et 
a!.. 2001). AMPK has been shown to inhibit both lipolysis and lipogenesis in adipose 
tissue (Winder et a!., 1999), and will do so under conditions of low cellular A TP levels. 
Thus, the generation of cellular energy in adipose tissue mitochondria may have 
implications on the status of whole body energy balance and it is therefore plausible that 
perturbation of this system can lead to obesity. Similarly, drugs that can target this system 
may be useful in the treatment of obesity. 
Chapter 1.5: Microarrays as useful tools for studying obesity. 
The advent of microarrays has provided a new tool for the study of complex 
diseases such as obesity. Microarrays facilitate the simultaneous quantification of 
thousands of different messenger RNA (mRNA) molecules in a single experiment. This 
aids in the study of complex diseases by determining what genes are expressed in a give 
cell, tissue, or organ, and how their expression patterns may be altered in the disease 
state. This is an especially powerful tool for the study of obesity as a large number of 
genes in a wide range of processes have been implicated in its etiology. The basic 
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principal of this technique relies on competitive hybridization of mRNA molecules to 
cDNAs or synthetic oligonucleotides on a glass slide. Detection of the mRNA molecules 
is accomplished by attaching dye molecules to the mRNA prior to hybridization, 
followed by detection of the fluorescent signal post hybridization. It is now possible to 
assay all known genes in the human genome in a single experiment, using mRNA from 
adipose tissue, or other tissue/organs that may be involved in the development of obesity. 
This allows for the detection of genes and the generation of genetic profiles that may be 
pathogenic with respect to obesity, or predispose an individual to obesity. 
Chapter 1.6: Adipose tissue microarray studies 
A number of microarray studies reporting gene expression profiles in adipose 
tissue have been reported in animal models and humans. These studies have shown that 
genes involved in lipolysis, as well as many other biological processes, may be involved 
in the pathophysiology of obesity (Gomez-Ambrosi et al., 2004, Castro-Chavez et al., 
2003, and others). To date, the focus has mainly been on the visceral adipose tissue 
depot, as it has been established that the accumulation of visceral fat is associated with a 
higher risk for obesity related phenotypes (Mohamed-Ali et al., 1998), such as 
hypertension, insulin resistance, impaired insulin secretion, type 2 diabetes, 
cardiovascular disease, and hyperlipidemia (Montague et al., 1997, Lubrano-Berthelier et 
al., 2004). Yang and associates (2003) generated gene expression profiles from visceral 
adipose tissue and discovered that a number of genes encoding receptors for appetite 
regulating peptides are produced in this depot, including leptin, melanin concentrating 
hormone (MCH), cholecystokinin ( CCK), neuropeptide Y (NPY), and orexin. This 
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suggests a regulation of appetite by adipose tissue through autocrine/paracrine 
mechanisms (Yang et al., 2003). While generation of expression profiles for visceral 
adipose tissue may serve as a reference for future physiological and pathophysiological 
studies concerning obesity (Yang et al., 2003), comparisons of differential expression 
profiles in fat depots and in lean and obese individuals may be much more informative in 
determining specific obesity causing genes. 
Differential expression profiles from subcutaneous and visceral fat depots have 
also been generated as a means to elucidate obesity candidate genes, and to determine the 
genetic factors influencing metabolic differences between the two depots. Profiles 
generated using Affymetrix human U13A chips revealed a total of 347 transcripts that 
differ in expression between the two fat depots (Vohl et al., 2004). These include genes 
involved in Wnt signaling, lipolytic stimuli, cytokine secretion, as well as CEPBA and 
HOX genes. Furthermore, the gene encoding phospholipid transfer protein (PLTP) was 
shown to be up-regulated in visceral when compared to subcutaneous adipose tissue of 
obese individuals (Linder et al., 2004). Evidence suggests that expression of PLTP in 
visceral adipose tissue influences plasma concentrations of PL TP, which has been 
associated with plasma HDL and insulin resistance (Riemens et al., 1998). Although 
correlations between the expression of genes in visceral and subcutaneous depots is high 
(Vohl et al., 2004), the detection of numerous transcripts differentially expressed between 
depots supports the idea that the two depots may function in different ways with respect 
to obesity. 
Studies comparing expression profiles of visceral adipose tissue between lean 
and obese individuals have yielded numerous obesity candidate genes with highly diverse 
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functional roles. Genes involved in lipolysis activation were down-regulated in visceral 
adipose tissue from obese individuals, while genes involved in lipolysis repression were 
up-regulated (Gomez-Ambrosi et al., 2004). This suggests a genetic influence on the rate 
of lipolysis that differs between lean and obese people. Furthermore, genes involved in 
processes such as cell proliferation, immune response, angiogenesis, metabolism, and 
signal transduction may play a role in the etiology of obesity as they have also been 
shown to be differentially regulated between visceral adipose tissue from lean and obese 
persons (Gomez-Ambrosi et al., 2004). Visceral adipose tissue expression profiles have 
also shown that complement proteins are up-regulated in obese persons, which suggests 
that obesity may result, in part, from an innate immune response in the adipose tissue 
(Gabrielsson et al., 2003). 
The role of subcutaneous adipose tissue gene expression in the etiology of obesity 
has not been rigorously studied. However, it is accepted that this depot is more sensitive 
to the antilipolytic effects of insulin (Linder et al., 2004), and has higher levels of leptin 
expression (Vohl et al., 2004), which may indicate a role for this depot in the 
development of obesity and related metabolic disorders. Investigations into genes 
expressed in subcutaneous adipose tissue have yielded numerous obesity candidate genes 
that, similar to the visceral depot, display a wide range of biological functions. These 
include regulation of gene expression, cell structure and motility, cell signaling, cell 
division, and cell defense (Gabrielsson, 2000). 
Recently, changes in expression profiles of subcutaneous adipose tissue in 
response to a very low caloric diet (VLCD) have been generated in lean and obese 
women. Two distinct clusters were revealed, one cluster of genes up-regulated by the 
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VLCD, and one that was repressed by VLCD (Clement et al., 2004). The fact the gene 
expression in SCAT can be induced or repressed in response to alterations in energy 
balance provides supporting evidence of a role for this depot in the development of 
obesity. However much work is still needed regarding SCAT and its role in the 
pathophysiology of obesity. First, we lack information concerning the comprehensive 
gene expression profile of SCAT in both lean and obese humans at baseline, which is 
critical for further studies. Second, can the gene expression profiles generated from 
subcutaneous adipose tissue define lean and obese individuals at baseline? Although 
Clement and associates show two distinct clusters of genes that are deregulated in 
response to VLCD, there is no data presented as to possible clustering of genes at 
baseline. 
Chapter 1.7: Thesis rationale. 
The main goal of the current work was to assay gene expression m the 
subcutaneous adipose tissue oflean and obese young men. This allows for insight into the 
pathophysiology of obesity by comparing lean and obese profiles and deducing how they 
may affect adipose tissue function. The generation of gene expression profiles at baseline 
will also provide a platform for further studies involving nutritional intervention. That is, 
we can assay gene expression in response to overfeeding or underfeeding, and compare 
profiles to those at baseline. Furthermore, we plan to determine if a gene expression 
profile exists that can accurately define an individual as lean or obese. The current study 
will be used to define this profile, which can then be tested using a second, independent 
cohort. 
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Another goal of the current work was to detennine if genetic variation in the 
Cocaine and Amphetamine Regulated Transcript ( CAR1) gene is associated with obesity 
or obesity related phenotypes in the Newfoundland population. This gene codes for a 
peptide which is produced predominantly in the hypothalamus and can regulate food 
intake in animal models (reviewed by Hunter et a/., 2004). As the number of samples in 
this study is small and the data and interpretation limited, this will be presented as an 
appendix to this thesis (Appendix 1). Appendix 2 contains an abstract for a publication 
in the American Journal of Clinical Nutrition, of which I am a co-author. That work 
involves the comparison of two methods for measuring body fat content in humans. 
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Chapter 2: Materials and Methods 
Chapter 2.1: Subject recruitment for microarray study. 
A total of 16 male volunteers between the ages of 20-27 were recruited from the 
Canadian province of Newfoundland and Labrador (NL). Subjects were healthy without 
metabolic or endocrine disorders, and were not on medication for lipid metabolism. All 
subjects reported having a stable weight (±5 pounds) within the previous six months. This 
study was approved by the Ethics Committee of Memorial University of Newfoundland, 
and all participants gave written informed consent to participate. Subjects were defined as 
lean or obese based on body fat percentage (%BF), as assessed by dual energy X-ray 
absorptiometry (DXA) after a 12 hour fast. Lean individuals were defined as :5 20 %BF, 
while obese individuals were defined as 2: 25 %BF (Bray et al., 1998). 
Chapter 2.2: Blood sampling and serum analysis 
A fasting blood sample was taken from all volunteers for the current study. Blood 
samples were taken immediately before the adipose tissue biopsy. Serum concentrations 
of glucose, triglycerides (TG), total cholesterol, and HDL cholesterol (HDL-C) were 
measured using Synchron reagents and performed on an Lx20 (Beckman Coulter Inc, 
CA., U.S.A) in the biochemistry labs of the St. John's Healthcare Corporation. LDL-
cholesterol (LDL-C) was calculated using the following formula: (total cholesterol) -
(HDL-C) - (TG/2.2). Serum insulin levels were measured on an Immulite immunoassay 
analyzer (DPC, CA., U.S.A). The homeostasis model assessment (HOMA) was used to 
estimate insulin resistance (HOMA-R). Serum was stored at -80° C. Data obtained that 
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were not normally distributed were transformed using the natural log for subsequent 
analysis (ie. TG, insulin, and HOMA-R). 
Chapter 2.3: Adipose tissue biopsy 
Subcutaneous adipose tissue samples were obtained from eight lean and eight 
obese males following a I2 hour fast. Adipose tissue was removed from the sub-
umbilical region. A local anesthetic was used, which was composed of I 0 cc of lidocaine 
in dilute bupivacaine (40cc of 0.25% bupivacaine in 250 cc of normal saline). 
Approximately 4 g of subcutaneous adipose tissue was removed by physicians, and 
immediately flash frozen in liquid nitrogen, and stored in liquid nitrogen until further 
analysis. 
Chapter 2.4: RNA isolation and preparation 
Approximately 500 mg of adipose tissue was homogenized using a rotor-stator 
homogenizer (Brinkmann Instruments, NY. U.S.A.), and total RNA isolated from adipose 
tissue using RNeasy lipid tissue midi kit (Qiagen, CA., U.S.A). This process involves 
chloroform separation of DNA, RNA, and organic components, followed by binding of 
the RNA to a silica gel membrane for purification. While the RNA was bound to the 
membrane, an additional DNase digestion was performed to remove possible DNA 
contamination. RNA concentration and purity were determined spectrophotometrically 
(Eppendorf, Hamburg Germany), and integrity was assessed on a 21 00 bioanalyzer 
(Agilent Technologies, CA., USA). For assessment of RNA integrity, approximately I 0 
ng of total RNA in 1 ul ofRNase free water was used in each reaction. 
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Chapter 2.5: RNA amplification and labeling 
Total RNA from the adipose tissue samples was amplified using a low input 
linear amplification kit (Agilent Technologies), based on the T7 linear amplification 
system, which has been validated for use in microarray experiments (Schneider et a/., 
2004). 300 ng of total RNA was used for each amplification. The reaction mixture for 
this process was as follows: 4.0 ul of first strand buffer, 2.0 ul of 0.1 M DTT, 1.0 ul of 10 
mM dNTP mix, 1.0 ul ofMMLV-RT, and 0.5 ul RNase OUT per reaction. The reaction 
cycle was as follows: 2 hours at 40° C, 15 minutes at 65°C, followed by 5 minutes at 4°C. 
The end result of this process is eDNA synthesis from the total RNA input. 
In separate parallel reactions, each amplified sample was labeled with either 
cyanine 3 (Cy3) or Cyanine 5 (Cy5) (Perkin Elmer, MA, U.S.A). Co-currently, amplified 
reference RNA (Stratagene, CA., U.S.A) was also labeled with Cy3 or Cy5. The reaction 
mixture was as follows: 15.3 ul of nuclease-free water, 20 ul of 4X transcription buffer, 
6.0 ul ofO.l M DTT, 8.0 ul ofNTP mix, 6.4 ul 50% PEG, 0.5 ul ofRNase OUT, 0.6 ul 
of inorganic pyrophosphatase, and 0.8 ul of T7 RNA polymerase per reaction. The 
reaction was incubated at 40° C for 2 hours. Samples were then purified using RNeasy 
mini elute kit (Qiagen). The fundamental aspects of the amplification and labeling 
processes are summarized in Figure 3. Hybridization of amplified, labeled RNA samples 
was accomplished by use of Agilent's in situ hybridization kit. 
Chapter 2.6: Array Hybridization and imaging 
Each Cy3 or Cy5 labeled sample was competitively hybridized with a Cy5 or Cy3 
labeled universal human reference RNA, to Agilent's 44K whole human genome chip. A 
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RNA from sample 1 
5'--------AAAA 3' 
l 
2nd strand--------AAA~ 
eDNA ~
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Figure 3: The amplification and labeling of RNA from adipose tissue. During the 
amplification process, total RNA is amplified into eDNA. An RNA copy is then made of 
each eDNA, and labeled using either Cy3 or Cy5. The two amplified, labeled samples are 
then competitively hybridized to the microarray. 
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total of 1.50 Jlg of amplified, labeled RNA was hybridized to each array; 750 ng of 
sample and 750 ng of reference RNA. Reverse hybridization was performed (one array 
hybridized with Cy3 labeled sample and Cy5 labeled reference RNA, and a second array 
hybridized with Cy5 labeled sample and Cy3 labeled reference RNA). Arrays were 
hybridized at 60°C for 17.5 hours. Microarrays were washed with I% saline-sodium 
citrate Buffer (SSC) for 3 minutes, then in 0.1% SSC for three minutes. A final 1 minute 
wash was completed, which contained an ozone scavenger dissolved in an acetonitrile 
solution. 
All arrays were scanned with the ScanArray Express (Perkin Elmer, MA., U.S.A), 
with two lasers; one set at 550 nm that excites Cy3, and one set at 650 nm that excites 
Cy5. Both lasers were set to 80% power to avoid excess overexposed features. All arrays 
were quantified using Imagene software, version 5.6 (Biodiscovery Inc., CA., U.S.A.). 
Feature quality was determined using default parameters. 
Chapter 2. 7: Statistical Analysis 
Raw data was determined for each array, and transformed for subsequent analysis 
using GeneSight lite version 5.6 (Biodiscovery Inc). First, local background intensities 
were subtracted, then the ratio of sample intensity to universal human reference RNA 
intensity was computed. Spots flagged for quality measures were deleted from each array 
individually. Briefly, spots where the signal was not at least twice that of the local 
background were deleted. Also, spots that were of an irregular shape, or had a reported 
signal intensity less than zero were also deleted. The remaining data (average of 21 989 
spots per array) were transformed to a logarithmic scale (base 2), and then normalized 
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using Z-scores to ensure a normal distribution of data on all arrays. A mean value was 
determined for the two arrays for each sample, and was used in all analyses. 
A paired design was used to minimize the potential influence of confounding 
factors in the current study. Each obese volunteer was paired with a lean volunteer based 
on physical characteristics such as age, height, physical activity levels, smoking status 
and alcohol consumption. That is, a mean ratio for each obese volunteer was compared 
directly to a mean ratio for the designated paired lean individual. 
Stringent criteria were used to determine genes that had significantly increased or 
decreased expression in obese adipose tissue when compared to lean. First, genes were 
selected on the basis that an overall average increase or decrease of 1.5 fold existed 
between the eight pairs. A total of 11 134 genes fulfilled this criterion. Furthermore, only 
genes which displayed this regulation pattern in at least 5 out of the 8 pairs were included 
for further analysis. This criterion ensures that a gene is not called significant because of 
a large signal difference between a small number of pairs. A total of 5361 genes remained 
and were tested for significance using paired t tests. A p value ofO.Ol or less was taken to 
be statistically significant, leaving a total of 318 genes. Using this level of significance, 
we estimate the maximum false discovery rate (FDR) will not exceed 8.4%. An analysis 
of the estimated FDR at different levels of significance is seen in Table 2. SPSS for 
windows, Version 11.5 was used for the paired statistical analysis. 
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Table 2: Comparison of false discovery rates at different levels of significance 
Level of significance 
p :s 0.001 
p :s 0.005 
p :s 0.01 
p :s 0.05 
Number of genes 
called significant 
28 
102 
318 
917 
False discovery rate 
10.0% 
12.0% 
8.4% 
14.5% 
FDR calculated using the following formula: [ { (N)(Y)/2} I Z] x 100%, where N is the 
number of genes being compared, Y is the level of significance, and Z is the number of 
genes called significant at level Y. 
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Chapter 2.8: Analysis of gene ontology 
An analysis of gene ontology was undertaken to detennine if any set of genes 
involved in similar biological processes, molecular function, or found in a particular 
cellular component were over represented in our list of significant differentially regulated 
genes. This was accomplished by comparing our list of significantly up- or down-
regulated genes with the list of all genes on the Agilent whole human genome chip (up 
and down-regulated genes were compared separately to the reference list). The expected 
number of genes for a specific ontology term was compared to the observed using a chi-
square test, with a p value :S 0.01 taken to be significant. This was performed using Gene 
ontology Tree Machine software (http://genereg.oml.gov/gotm). 
Chapter 2.9: Cluster analysis 
The 16 SCAT samples were clustered based on the expression ratio of selected 
gene sets to determine if any set exists that can accurately distinguish lean from obese 
adipose tissue. Hierarchical and K-means clustering (k=2) was undertaken using gene 
sets based on significance values (p values :S 0.001, :S 0.005, and :S 0.01). Specific gene 
sets based on ontology terms were also used for sample clustering. Euclidean distances 
were used for all clusters, based on average linkage. Genelinker Gold 2.0 (Improved 
Outcomes Software, ON. Canada) was used to perform all clustering analyses. 
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Chapter 3: Results 
Chapter 3.1: Physical and biochemical characteristics of the subjects 
Physical and biochemical characteristics of the subjects are shown in table 3. 
Obese subjects were defined as 2: 25.5 %BF, while non-obese were defined as ::::; 20.0 
%BF. Obese individuals showed increased levels of total cholesterol, LDL cholesterol, 
and triglycerides. This difference was statistically significant at the p ::::; 0.01 level. As 
shown by the homeostasis assessment model for insulin resistance, obese volunteers were 
also more insulin resistant than lean volunteers, which was also significant at the p :S 0.01 
level 
Chapter 3.2: Analysis of RNA integrity 
To ensure that total RNA isolated from adipose tissue contained intact mRNA 
transcripts, we measured RNA integrality on a 2100 bioanalyzer. Representative 
electropherograms are shown in Figure 4. Two distinct peaks are shown in each 
electropherogram, indicating intact 28S and 18S ribosomal RNA. Thus, it can be inferred 
that mRNAs in each sample are intact as well. 
Chapter 3.3: Characterization of significantly differentially expressed genes 
Using a paired study design, we identified 318 genes and transcripts differentially 
expressed in SCAT from lean and obese persons at baseline. Of those 318, 232 (73.0%) 
have defined gene names, with 151 (65.1 %) of those 232 genes having associated 
biological processes defined by gene ontology terms. Figure 5 shows the relative 
abundance of ontology terms associated with the differentially expressed genes. Table 4 
shows all the genes differentially expressed between lean and obese adipose 
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Table 3: Physical and biochemical characteristics of lean and obese subjects 
Lean Obese 
Characteristic (n=8) (n=8) 
Age 21.9 (20-25) 23.3 (21-27) 
Height: (em) 180.0 (171.2-189.6) 176.2 (166.8-186.5) 
Weight: (kg) 74.7 (56.7-96.0) 94.5 (73.5-135.0)* 
BMI (kglm2) 23.1 (17.9-30.3) 30.6 (22.2-43.8)* 
%BF 14.9 (7.6-20) 30.5 (25.5-40.3)* 
Insulin (pmol/L) 46.19 (28.6-78.6) 90.71 (34.5-175) 
Glucose (mmol/L} 4.58 (1.9-5.2) 5.35 (4.5-6.5) 
TG (mmol/L)1 0.78 (0.42-1.11) 1.12 (0.79-1.55)* 
Total Chol (mmol/L) 3.82 (2.87-5.41) 4.85 (4.01-5.61)* 
HDL-C (mmol!L) 1.36 (0.94-1.52) 1.48 (0.95-3.6) 
LDL-C (mmol!L} 2.11 (1.29-3.26) 2.87 (1.59-3.68)* 
HOMA-R1 1.31 (0.48-2.49) 3.13 (0.96-5.26)* 
Data presented as mean, range in parenthesis 
1 statistical testing performed on log transformed data (base e) 
* indicates means are statistically different between lean and obese, p S 0.01, student t 
test. 
HOMA-R: homeostatic model for insulin resistance 
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Figure 4: Representative electropherograms of total RNA isolated from adipose tissue. A 
and B represent lean samples, while C and D represent obese samples. In each panel, the 
three peaks (from left to right) represent the marker, 18s RNA, and 28s RNA. The two 
distinct peaks for ribosomal RNA are indicative of intact total RNA. 
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Figure 5: Relative abundance of Gene ontology terms (biological process) associated 
with 232 differentially expressed genes between obese and lean SCAT. 
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Table 4: All differentially expressed genes with def"med names, organized by 
biological process. 
HUGO name Description Fold Change* p-value 
Transport 
SLC25A13 solute carrier family 25, member 13 0.53 0.0036 
SLC25A22 solute carrier family 25, member 22 0.50 0.0041 
SLC9A3t solute carrier family 9, isoform 3 0.31 0.0110 
RABGEF1t RAB guanine nucleotide exchange factor 0.54 0.0009 
SEC15Llt SEC15-like 1 (S. cerevisiae) 0.53 0.0051 
MRPL45t mitochondrial ribosomal protein 0.44 0.0051 
FBXL5t F -box and leucine-rich repeat protein 5 0.62 0.0116 
ATP5S ATP synthase, mitochondrial FO complex, subunit s 0.61 0.0141 
CECR2 cat eye syndrome chromosome region, candidate 2 0.50 0.0110 
FLJ43855 similar to NA +- and CL--dependent creatine transporter 0.51 0.0066 
LAX hypothetical protein FLJ20340 0.55 0.0080 
TLOC1 translocation protein 1 0.48 0.0068 
KIAA0528 KIAA0528 gene product 0.42 0.0063 
RAB14t RAB14, member RAS oncogene family 0.57 0.0075 
SLC16A3 solute carrier family 16, member 3 2.11 0.0109 
LOC136306 Hypothetical protein LOC136306 3.43 0.0057 
TNPOl transportin 1 , transcript variant 1 , 2.78 0.0100 
LOC203427 similar to solute carrier family 25, member 16 10.58 0.0057 
TSAP6t Dudulin2 1.74 0.0071 
NUPLl nucleoporin like 1 2.55 0.0013 
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EROILB EROl-like beta 4.18 0.0034 
Electron transport 
NDUFB5 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5 0.38 0.0015 
NDUFB6 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6 0.39 0.0006 
C6orfl07 chromosome 6 open reading frame 0.58 0.0120 
MGC25181 hypothetical protein MGC25181 0.51 0.0144 
IL4Il interleukin 4 induced 1, transcript variant 2, 6.10 0.0107 
IVDt isovaleryl Coenzyme A dehydrogenase 3.89 0.0089 
Apoptosis 
SMNDClt survival motor neuron domain containing I 0.40 0.0072 
SIRTlt silent mating information regulation 2 homolog I 0.38 7.01E-05 
PAX3 paired box gene 3 0.34 0.0120 
PRODHt proline dehydrogenase (oxidase) 0.49 0.0056 
APLPl amyloid beta (A4) precursor-like protein 1 2.92 0.0121 
PHF17 PHD protein Jade-1 (JADE1), transcript variantS 2.51 0.0061 
API5 apoptosis inhibitor 5 2.27 0.0120 
IER3t immediate early response 3 2.35 0.0027 
ERCC2 excision repair cross-complementing group 2 6.08 0.0012 
ITGB2t integrin, beta 2, macrophage antigen 1 beta subunit 15.25 0.0129 
ROCKlt Rho-associated, coiled-coil containing protein kinase 1 2.10 0.0096 
Transcription 
TARDBP TAR DNA binding protein 0.59 0.0095 
IRX5 Unknown 0.52 0.0069 
ZHX2 zinc fingers and homeoboxes 2 0.34 0.0140 
GTF3C2 general transcription factor IIIC, polypeptide 2, beta 0.67 0.0140 
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SOX17 SRY (sex detennining region Y)-box 17 0.56 0.0003 
SNAPC4 small nuclear RNA activating complex, polypeptide 4, 0.63 0.0060 
CREB3L3 cAMP responsive element binding protein 3-like 3 0.67 0.0043 
EED embryonic ectoderm development, transcript variant 1 0.50 0.0084 
RBPSUHt recombining binding protein suppressor of hairless 0.49 0.0110 
ZNF295 zinc fmger protein 295 0.48 0.0112 
ZNF302 zinc fmger protein 302 0.53 0.0054 
ZNF160 zinc finger protein 160 0.58 0.0080 
ZFY zinc finger protein, Y-linked 0.42 0.0049 
ODAG ocular development -associated gene 0.58 0.0073 
JDP2 jun dimerization protein 2 8.50 0.0033 
NKX6-1 NK6 transcription factor related, locus 1 10.43 0.0143 
SBZF3 zinc finger protein SBZF3 7.81 0.0114 
ZNF541 zinc fmger protein 541 3.72 0.0124 
BRSK2 serine/threonine kinase 2 1.78 0.0118 
Cell adhesion 
LRRN5 leucine rich repeat neuronal5, transcript variant 1 0.47 0.0011 
NID2t nidogen 2 ( osteonidogen) 0.67 0.0055 
DCBLD1 discoidin, CUB and LCCL domain containing 1 0.54 0.0081 
AZGPl alpha-2-glycoprotein 1 0.39 0.0005 
MYBPC1 myosin binding protein C, slow type, transcript variant 1 8.68 0.0049 
SCARF2 scavenger receptor class F, member 2 transcript variant 1 2.53 0.0006 
WISP2 WNT1 inducible signaling pathway protein 2 2.49 0.0089 
GPLD1 glycosylphosphatidylinositol specific phospholipase D1 2.49 0.0072 
CYR61t cysteine-rich, angiogenic inducer, 61 2.82 0.0048 
30 
Signal transduction 
RAB18t RAS oncogene family, member 18 0.66 0.0087 
RAB33B member RAS oncogene family , member 33B 0.45 0.0047 
HTR1B5 hydroxytryptamine (serotonin) receptor 1 0.48 0.0144 
GPR109Bt G protein-coupled receptor 109B 0.41 0.0005 
NPB preproneuropeptide B 0.63 0.0076 
MAP4K4 mitogen-activated protein 4 kinase 4 0.43 0.0094 
GRBlOt growth factor receptor-bound protein 10 0.58 0.0041 
CAMKKl calcium/calmodulin-dependent protein kinase kinase 1 0.46 0.0020 
SHFM3t split hand/foot malformation (ectrodactyly) type 3 0.64 0.0111 
HTR1D5 hydroxytryptamine (serotonin) receptor ID 0.33 0.0040 
EFNB2t ephrin-B2 0.54 0.0073 
PPP2CBt protein phosphatase 2 , beta isoform 0.49 0.0071 
PPP2R2At protein phosphatase 2, regulatory subunit B 0.64 0.0062 
PRKAR2At cAMP dependant protein kinase, regulatory subunit alpha 9.47 0.0050 
OR51B4 olfactory receptor, family 51, subfamily B, member 4 8.36 0.0037 
SAG S-antigen; retina and pineal gland (arrestin) 4.36 0.0063 
FLJ14249 HS !-binding protein 3 4.29 0.0050 
Immunity/Defense response 
MSTlR macrophage stimulating 1 receptor 0.51 0.0046 
YYl YYl transcription factor 0.44 0.0150 
PLA2G7 phospholipase A2, group VII 15.74 0.0074 
ATRNt attractin transcript variant 2 4.16 0.0028 
DEFB118 defensin, beta 118 6.96 0.0074 
CXCL2 chemokine (C-X-C motif) ligand 2 5.00 0.0018 
CR2t complement component (3d/Epstein Barr virus) receptor 2 1.62 0.0098 
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Metabolism/Lipolysis 
PPP1CAt protein phosphatase 1, catalytic subunit, alpha transcript 0.52 0.0087 
PRKAR2Bt cAMP dependant protein kinase, regulatory subunit beta 0.31 0.0018 
AGL amylo-1, 6-glucosidase, 4-alpha-glucanotransferase, 0.48 0.0070 
pet pyruvate carboxylase , transcript variant A 0.40 0.0026 
BCKDHAt branched chain keto acid dehydrogenase E1, alpha 0.44 0.0123 
ENDOG endonuclease G 0.62 0.0067 
FASNt fatty acid synthase 0.63 0.0032 
DLST dihydrolipoamide S-succinyltransferase 0.52 0.014 
FAHD2A fumarylacetoacetate hydrolase domain containing 2A 0.65 0.0098 
ENPP6t ectonucleotide pyrophosphatase/phosphodiesterase 6 5.98 0.0103 
AGXT alanine-glyoxylate aminotransferase 4.44 0.0094 
FUK fucokinase 2.00 0.0009 
C14orfl75 chromosome 14 open reading frame 17 5 10.44 0.0088 
AGPAT4 1-acylglycerol-3-phosphate 0-acyltransferase 4 2.79 0.0035 
ACATE2t acyl-Coenzyme A thioesterase 2, mitochondrial 1.87 0.0104 
Protein Folding 
HSPD1t heat shock 60kDa protein I, transcript variant 1 0.32 0.0057 
TTC1t tetratricopeptide repeat domain 1 0.50 0.0078 
DNAJB6t DnaJ (Hsp40) homolog, subfamily B, member 6 0.50 0.0023 
FKBP5 FK506 binding protein 5 0.59 0.0124 
HCG3 HCG3 gene 0.58 0.0139 
PFDNlt prefoldin 1 0.65 0.0086 
Protein Ubiquination!Ubiquination Cycle 
TRIM4 tripartite motif-containing 4, transcript variant alpha, 0.37 0.0016 
ITCH itchy homolog E3 ubiquitin protein ligase 0.65 0.0116 
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FBX030 F-box protein 30 0.51 0.0105 
CNOT4 CCR4-NOT transcription complex, subunit 4 0.56 0.0062 
USP48 ubiquitin specific protease 48 0.60 0.0107 
USP25t ubiquitin specific protease 25 0.54 0.0029 
TRIM17 tripartite motif-containing 17 4.08 0.0101 
KIAA0804 KIAA0804 protein 4.62 0.0079 
Amine biosynthesis 
CTBP2t C-terminal binding protein 2 0.59 0.0113 
TMLHE trimethyllysine hydroxylase, epsilon 0.59 0.0004 
DHFR dihydrofolate reductase 0.62 0.0056 
Miscellaneous 
TSPYL3 TSPY-like 3 (TSPYL3) 0.39 0.0133 
PALMD palmdelphin 0.51 0.0057 
PGPEPI pyroglutamyl-peptidase I 0.61 0.0095 
TIMP4t tissue inhibitor of metalloproteinase 4 0.48 0.0010 
ADSSLlt adenylosuccinate synthase like 1, transcript variant 2 0.44 0.0028 
PESlt pescadillo homolog 1, containing BRCT domain 0.56 0.0065 
NEDD5 neural precursor cell expressed, develop. down-regulated 5 0.60 0.0076 
ClqTNF7 C 1 q and tumor necrosis factor related protein 7 0.46 0.0005 
TMPITt transmembrane protein induced by TNF alpha 0.37 0.0056 
CTGLFI centaurin, gamma-like family, member 1 0.55 0.0025 
C20orfl41 chromosome 20 open reading frame 141 0.54 0.0149 
TTLL3t tubulin tyrosine ligase-like family, member 3 0.50 0.0135 
NOP5/58 nucleolar protein NOP5/NOP58 0.64 0.0004 
MST4t Mst3 and SOKI-related kinase 0.52 0.0149 
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ZCCHC11 zinc fmger, CCHC domain containing 11 0.63 0.0126 
FLJ23588 CAP-binding protein complex interacting protein 1 0.61 0.0069 
FHOD3 formin homology 2 domain containing 3 0.29 0.0107 
IDI2 isopentenyl-diphosphate delta isomerase 2 0.52 0.0025 
YT521 splicing factor YT521-B 0.52 0.0031 
MRPS31t mitochondrial ribosomal protein S31 0.44 0.0115 
HS6ST3 heparan sulfate 6-0-sulfotransferase 3 3.64 0.0132 
OLFMl olfactomedin 1, transcript variant 2 4.75 0.0090 
MRC1 mannose receptor, C type 1 2.03 0.0021 
RNPEP arginyl aminopeptidase (aminopeptidase B) 18.13 0.0103 
ACTR3 ARP3 actin-related protein 3 homolog 3.77 0.0129 
DUSP7 dual specificity phosphatase 7 3.89 0.0089 
KIAA1008t KIAA1008 protein 8.60 0.0069 
NAPS A napsin A aspartic peptidase 6.22 0.0072 
TTLL4 tubulin tyrosine ligase-like family, member 4 13.69 0.0147 
No defined biological process 
AZI2 5-azacytidine induced 2 0.44 0.0004 
OSRF osmosis responsive factor 0.42 0.0033 
TUSC1 tumor suppressor candidate 1 0.50 0.0033 
CGI-62 CGI-62 protein 0.39 0.0022 
FLJ22794 FLJ22794 protein 0.44 0.0034 
FLJ20699 hypothetical protein FLJ20699 0.49 0.0033 
LOC92270 hypothetical protein LOC92270 0.60 0.0034 
HMGN1 high-mobility group nucleosome binding domain 1 0.59 0.0039 
METTL2 methyltransferase like 2 0.44 0.0048 
34 
TORC2 transducer of cAMP response element-binding protein 2 0.58 0.0131 
FLJ10241 hypothetical protein FU10241 0.57 0.0144 
ITPKC inositol 1 ,4,5-trisphosphate 3-kinase C 0.46 0.0149 
KIAA0182 KIAAO 182 protein 0.57 0.0134 
KIAA1164 hypothetical protein KIAA1164 0.64 0.0049 
FLJ11235 hypothetical protein FU11235 0.67 0.0131 
KLHL15 kelch-like 15 (Drosophila) 0.35 0.0061 
LOC133619 hypothetical protein MGC121 03 0.46 0.0131 
NOL7 nucleolar protein 7, 27kDa 0.65 0.0062 
FLJ13291 hypothetical protein FU13291 0.58 0.0065 
MESPI mesoderm posterior 1 0.25 0.0075 
MR-1 myofibrillogenesis regulator 1 0.46 0.0036 
HSPC129 hypothetical protein HSPC129 0.54 0.0035 
LOC51234 hypothetical protein LOC51234 0.50 0.0024 
FLJ38716 hypothetical protein FU38716 0.48 0.0015 
PRICKLE2 prickle-like 2 (Drosophila) 0.38 2.64E-05 
TMEM22 transmembrane protein 22 0.47 0.0003 
LOC440234 similar to hypothetical protein 0.57 0.0079 
LOC341333 similar to Heterogeneous nuclear ribonucleoprotein AI 0.54 0.0087 
MGC42493 hypothetical protein MGC42493 0.55 0.0092 
LOC339210 hypothetical protein LOC339210 0.51 0.0101 
FLJ10246 hypothetical protein FUI 0246 0.64 0.0101 
LOC56181 hypothetical protein RP1-317E23 0.51 0.0113 
HSPC159 HSPC159 protein 0.57 0.0122 
KIAA0892 KIAA0892 protein 0.67 0.0080 
ZNF575 zinc finger protein 575 0.47 0.0005 
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ELP4 elongation protein 4 homolog 0.67 0.0017 
LSM6 LSM6 homolog, U6 small nuclear RNA associated 0.56 0.0019 
C10orf24 chromosome 10 open reading frame 24 0.52 0.0056 
CPAMD8 C3 and PZP-like, alpha-2-macroglobulin domain 0.62 0.0068 
RTN4RL2 reticulon 4 receptor-like 2 0.64 0.0072 
PLEKHJI pleckstrin homology domain, family J member 1 0.43 0.0074 
PRKCL2 protein kinase C-like 2 0.57 0.0077 
CPNE4 copine IV 0.40 0.0086 
CLN8t ceroid-lipofuscinosis, neuronal 8 0.64 0.0092 
NUDT14 nucleoside diphosphate linked moiety X-type motif 14 0.52 0.0092 
ADHFEI alcohol dehydrogenase, iron containing, 1 0.61 0.0095 
PSPC1 paraspeckle component 1 0.54 0.0098 
BAGE B melanoma antigen 0.45 0.0098 
ZNF395 unknown 0.52 0.0107 
LENG4t leukocyte receptor cluster (LRC) member 4 0.54 0.0119 
C20orf141 chromosome 20 open reading frame 141 0.54 0.0149 
C5orf18t chromosome 5 open reading frame 18 0.50 0.0060 
PRRG3 proline rich Gla (G-carboxyglutamic acid) 3 0.48 0.0122 
FLJ11301 hypothetical protein FU11301 2.45 0.0064 
HCA112 hepatocellular carcinoma-associated antigen 112 1.57 0.0073 
LOC389903 similar to Taxol resistant associated protein 3 (TRAG-3) 2.13 0.0081 
PVR poliovirus receptor 5.33 0.0009 
MUM1Ll melanoma associated antigen (mutated) 1-like 1 4.40 0.0058 
C20orf40 chromosome 20 open reading frame 40 3.25 0.0044 
KIAA0635 KIAA0635 protein 2.47 0.0081 
KIAA0907 KIAA0907 protein 2.39 0.0031 
36 
KIAA1720 KIAA1720 protein 4.77 0.0094 
LOC92345 hypothetical protein BC008207 8.67 0.0048 
RGAG1 retrotransposon gag domain containing 1 5.26 0.0101 
TMED4 transmembrane emp24 protein transport domain 4 6.10 0.0107 
FLJ38507 colon carcinoma related protein 4.38 0.0144 
GR6 putative GR6 protein 2.98 0.0144 
NRG4 neuregulin 4 3.33 0.0047 
FLJ22582 hypothetical protein FLJ22582 2.34 0.0112 
FLJ20195 hypothetical protein FLJ20195 3.95 0.0113 
DOK3 docking protein 3 2.49 0.0131 
PIWIL4 piwi-like 4 (Drosophila) 4.28 0.0129 
GBL G protein beta subunit-like 12.80 0.0124 
UNC93B1 unc-93 homolog B 1 3.61 0.0007 
ACP5t acid phosphatase 5, tartrate resistant 4.01 0.0050 
KIAA0853 KIAA0853 3.39 0.0051 
KIAA1919 K1AA1919 6.91 0.0056 
C9orf138 chromosome 9 open reading frame 138 11.36 0.0087 
C20orf22 chromosome 20 open reading frame 22 13.49 0.0098 
SAMSN1 SAM and SH3 domain, and nuclear localisation signal, 15.47 0.0099 
RTN4IP1 reticulon 4 interacting protein 1 3.16 0.0119 
* Fold change presented as obese/lean 
significance testing performed using paired-t tests 
t indicates previous reports of adipose tissue expression 
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tissue as defined by biological processes. Genes involved in transport and transcription 
were the most abundant, comprising 13.4% and 12.6% of the genes with defined 
ontologies, respectively. Genes involved in signal transduction and metabolism were also 
abundant, comprising 11.3% and 9.9% of genes with defined ontologies, respectively. 
Furthermore, only 51 of the genes with defined names have been previously shown to be 
expressed in human adipose tissue. Thus, we report a total of 181 defined genes that, to 
our knowledge, have not been previously reported as expressed in adipose tissue. A total 
of 87 potential genes without defined names were significantly differentially expressed 
between lean and obese individuals. Of these 87 potential genes, 33 were up-regulated in 
obese subjects (Table 5), while 54 were down-regulated in obese subjects (Table 6). 
These potential genes represent EST's and open reading frames. 
Chapter 3.4: Gene ontology (GO) analysis 
Gene ontology analysis revealed an over-representation of genes involved in 
specific biological processes as differentially expressed between lean and obese 
individuals. These processes include cell adhesion, apoptosis, cellular morphogenesis, 
inflammatory response, and cell growth (Figure 6), which were up-regulated in obese 
adipose tissue. Similarly, Figure 7 shows that genes involved in ATP coupled electron 
transport, NADH dehydrognease activity, and carrier activity which includes both 
hydrogen and sodium ion transporters, amine biosynthesis, and unfolded protein binding 
proteins were statistically over-represented in our list of down-regulated genes in obese 
adipose tissue. With respect to cellular component ontology terms, genes 
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Table 5: Potential genes without def"med names, that are up-regulated in obese 
adipose tissue 
Systematic Name Fold change* p-value Systematic Name Fold change* p-value 
AK096606 1.72 0.0002 BC017202 3.89 0.0089 
AW316654 7.18 0.0011 THC2107966 53.57 0.0092 
THC2131432 2.11 0.0020 THC2165289 1.78 0.0099 
A 24 P831005 2.36 0.0021 A 23 P9707 12.21 0.0099 
A 23 P157695 11.06 0.0032 THC2051081 7.07 0.0102 
BC004382 22.06 0.0035 A 24 P307395 1.50 0.0103 
A 24 P517355 3.43 0.0037 AK024304 119.69 0.0104 
AF086548 4.14 0.0044 A 32 P179199 5.11 0.0105 
BU731317 1.98 0.0048 A 24 P409772 1.67 0.0110 
AB002439 15.20 0.0052 AK026328 3.72 0.0110 
A 24 P644556 16.45 0.0069 A 32 P18300 9.15 0.0117 
THC2141858 10.87 0.0073 AK022227 12.80 0.0124 
A 24 P578437 24.96 0.0076 THC2086431 3.47 0.0124 
X61177 3.62 0.0082 AF007131 2.89 0.0130 
THC2175701 2.25 0.0086 ENST00000333662 5.18 0.0136 
AF278760 3.03 0.0087 AK055716 9.04 0.0148 
THC2105601 2.49 0.0040 
*Fold change presented as obese/lean 
Significance testing performed using paired t tests 
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Table 6: Potential genes without def"med names that are down-regulated in obese 
adipose tissue. 
Systematic Name Fold change* p-value Systematic Name Fold change* p-value 
A 32 P86517 0.30 0.0004 AF119848 0.36 0.0083 
BC038098 0.64 0.0011 BC010544 0.47 0.0086 
AL832534 0.54 0.0011 A 23 P51269 0.45 0.0086 
ENST00000297317 0.60 0.0017 NP511100 0.56 0.0087 
THC2088849 0.59 0.0087 A 32 P175557 0.64 0.0092 
A 32 P120818 0.56 0.0019 THC2173367 0.63 0.0092 
A 24 P846755 0.33 0.0020 A 24 P914102 0.52 0.0093 
AK026896 0.46 0.0021 AK000380 0.43 0.0094 
A 24 P24332 0.56 0.0026 ENST00000328411 0.50 0.0100 
BC009800 0.63 0.0027 BX101146 0.29 0.0106 
A 32 P200092 0.61 0.0031 THC2135324 0.62 0.0106 
THC2088623 0.46 0.0034 BC016022 0.51 0.0110 
A 24 P556328 0.60 0.0043 BC046172 0.47 0.0112 
CR609588 0.66 0.0048 A 24 P927902 0.32 0.0113 
AF086388 0.41 0.0048 AK091744 0.52 0.0115 
THC2174703 0.60 0.0054 A 24 P24786 0.45 0.0123 
BE537483 0.46 0.0055 AF086527 0.67 0.0129 
BC036435 0.64 0.0058 AK056401 0.44 0.0130 
A 23 P39251 0.38 0.0067 BC030112 0.51 0.0132 
A 32 P95502 0.66 0.0070 THC2209865 0.58 0.0134 
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A 24 P307443 0.49 0.0070 
AK001936 0.39 0.0071 
A 24 P916423 0.39 0.0075 
A 24 P938357 0.29 0.0077 
A 24 P477048 0.31 0.0078 
ENST00000311218 0.50 0.0080 
A 23 31348 0.51 0.0065 
*Fold change presented as obese/lean 
Significance testing performed using paired t tests 
BC017590 0.58 0.0139 
A 24 P384239 0.37 0.0141 
THC2131163 0.64 0.0141 
THC2050410 0.46 0.0149 
A 24 P516728 0.52 0.0081 
THC2077398 0.55 0.0045 
A 24 P882309 0.51 0.0110 
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Figure 6: Gene classifications statistically over-represented in obese (up-regulated). 
Gene ontology classifications based on biological process ontology terms only. Ontology 
classifications are not mutually exclusive; any gene can exist in more that one category. 
Difference between observed and expected are statistically significant (P S 0.01), based 
on chi-squared analysis. http://genereg.oml.gov/gotm. Expected values calculated from 
the number of genes associated with an ontology term on the Agilent whole human 
genome chip. 
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Figure 7: Gene classifications statistically over-represented in SCAT from obese subjects 
(down-regulated). Gene ontology based on biological process (Amine biosynthesis, ATP 
coupled electron transport), cellular component (mitochondrion), and molecular function 
(all others). Ontology classifications are not mutually exclusive; any gene can exist in 
more that one category. Difference between observed and expected are statistically 
significant (P ~0.01), based on chi-squared analysis. http://genereg.oml.gov/gotm. 
Expected values calculated from the number of genes associated with an ontology term 
on the Agilent whole human genome chip. 
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with functions in the mitochondria were over-represented in our list of down-regulated 
genes. 
Chapter 3.5: Supervised clustering of genes and samples 
Supervised clustering was undertaken to determine which, if any, set of gene 
expression values could accurately distinguish between lean and obese individuals. 
Hierarchical and K-means clustering was first performed on gene sets based on 
significance values. Thus, genes with p values :::; 0.001, 0.005, 0.01, and 0.05 were 
clustered as separate gene sets. Using this approach, the clustering algorithms could not 
group obese samples separately from the lean samples with a high degree of specificity 
(data not shown). 
Supervised clustering was also performed using gene sets based on ontology 
terms. Specific gene sets were built using genes that had statistically over- represented 
ontology terms. Using this rationale, we identified a set of 27 genes that clustered obese 
samples separately from the lean samples with a high degree of specificity. Using a K-
means clustering approach (K =2), all obese samples were clustered separately from the 
lean samples, indicating a specificity of 100% (Figure 8). However this specificity was 
reduced using a hierarchical clustering algorithm. Using this approach, two main clusters 
were generated, one containing seven lean and one obese sample and the other containing 
seven obese and one lean sample, resulting in a specificity of 87.5% (Figure 9). All 
genes contained in this cluster, and associated gene ontology terms are shown in table 7. 
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Obese8 
Obese7 
Obese6 
Obese5 
Obese4 
Obese3 
Obese2 
Obese1 
LeanS 
Lean7 
Lean6 
Lean5 
Lean4 
Lean3 
Lean2 
Lean1 
Figure 8: K means (K=2) clustering of samples using a 27 gene set comprised of genes 
with similar ontology terms. Red, black, and blue indicates expression ratio 
(sample/reference) above the median, equal to, and below the median respectively. All 
obese samples clearly cluster separately from lean. 
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Obese5 
Obese3 
Obese6 
Obese2 
Obese4 
Lean1 
Obese1 
Obese8 
Lean7 
Lean3 
Obese7 
Lean4 
Leana 
Lean6 
Lean5 
Lean2 
A 
B 
Figure 9: Hierarchical clustering of samples using a 27 gene set comprised of genes 
with similar ontology terms. Red, black, and blue indicates expression ratio 
(sample/reference) above the median, equal to, and below the median respectively. 2 
main clusters are generated, one containing seven obese samples and one lean (A), and 
the other containing seven lean samples and one obese (B). 
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Table 7: Genes contained in the 27 gene set cluster that accurately distinguishes 
between obese and non-obese young men. 
Gene symbol 
SLC25A13 
MRPS31 
ENDOG 
HSPDI 
NDUFB5 
NDUFB6 
PC 
PRODH 
BCKDHA 
SLC25A22 
MRPL45 
C60RF107 
PPP1CA 
PPP2CB 
SLC9A3 
DEFB118 
GPLD1 
APLP1 
ITGB2 
MYBPC1 
WISP2 
SCARF2 
Gene name 
solute carrier family 25, member 13 
mitochondrial ribosomal protein S31 
endonuclease G 
heat shock 60kDa protein 1 
ubiquinone 1 beta subcomplex, 5 
ubiquinone 1 beta subcomplex, 6 
pyruvate carboxylase 
Proline dehydrogenase 
branched chain keto acid dehydrogenase E1 
solute carrier family 25, member 22 
mitochondrial ribosomal protein 
chromosome 6, open reading frame 7 
protein phosphatase 1, catalytic subunit 
protein phosphatase 2 beta isoform 
solute carrier family 9, member A3 
defensin, beta 118 
Associated GO term 
transport, mitochondria 
mitochondria 
mitochondria 
protein folding, mitochondria 
electron transport, mitochondria 
electron transport, mitochondria 
metabolism, mitochondria 
Apoptosis, mitochondria 
metabolism, mitochondria 
transport, mitochondria 
transport, mitochondria 
electron transport, mitochondria 
metabolism, lipolysis 
signal transduction 
transport, mitochondria 
immunity, defense response 
glycosylphosphatidylinositol phospholipase D I cell adhesion 
amyloid beta (A4) precursor-like protein 1 apoptosis 
integrin, beta 2, macrophage antigen 1 apoptosis, cell adhesion 
myosin binding protein C, slow type cell adhesion 
WNTl inducible signaling pathway protein 2 cell adhesion 
scavenger receptor class F, member 2 cell adhesion 
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ERCC2 
ROCKl 
PHF17 
API5 
IER3 
excision repair cross-complementing group 2 apoptosis 
Rho-associated, coiled-coil containing kinase 1 apoptosis 
PHD protein Jade-1 
apoptosis inhibitor 5 
immediate early response 3 
apoptosis 
apoptosis 
apoptosis 
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Chapter 4: Discussion 
Chapter 4.1: Numerous biological processes may be involved in the pathophysiology 
of obesity. 
Numerous studies have been conducted that examine the gene expression profile 
of adipose tissue, but most have been limited by the number of genes and/or ESTs 
contained on the microarray itself. Here, for the first time, we report the expression 
profile of subcutaneous adipose tissue and how it differs between obese and non-obese 
young men, using whole human genome microarrays. As a result, we have not only been 
able to confirm trends discovered in previous microarray studies, but have also 
discovered novel biological trends and obesity candidate genes that can serve as a basis 
for future obesity related research. 
For many years, the control of the rate of lipolysis and lipogenesis has been the 
main avenue of obesity related research. However many other processes are now thought 
to be involved, including, inflammation (Clement et al., 2004) apoptosis (Aubin et al., 
2004; Duff et al., 2005), and cell adhesion (Abella et al., 2004; Eguchi et al., 2004). By 
comparing our list of differentially expressed genes with all the genes on the Agilent 44K 
array, we have identified a statistical over-representation of genes involved inflammation, 
apoptosis, cell adhesion and cellular morphogenesis, as well as others. Genes involved in 
these processes were found to have increased expression in the subcutaneous adipose 
tissue of obese individuals, indicating potential roles for these processes, and the genes 
involved, in the development of obesity. Furthermore, genes with an ontology 
classification of inflammation, apoptosis, cell adhesion, or cellular morphogenesis were 
included in the set of genes that correctly groups obese from non-obese subjects. This 
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cluster will be tested in future investigations to detennine if it can accurately predict 
obesity in a second cohort of subjects, and to determine if these expression values change 
in response to nutritional challenges. Thus, all of the genes contained in this cluster 
represent possible obesity candidate genes for further research. 
Chapter 4.2: Mitochondrial function and ATP synthesis may be deregulated in 
young men. 
The role of mitochondrial function and cellular_ATP concentration has not been 
rigorously studied with respect to obesity. However, perilipin null mice, which have a 
lean phenotype and are resistant to diet induced obesity, demonstrate increased 
expression levels of genes involved in ATP synthesis (Castro-Chavez et al., 2003). Our 
results indicate a reduction in the expression of a number of genes with functions in the 
mitochondria, four of which are directly involved in ATP coupled electron transport. 
Specifically, we observed a 2.6 fold decrease in NDUFB6 and NDUFB5, which comprise 
2 of the ubiquinone oxidoreductase complex I subunits of the mitochondrial electron 
transport chain. Numerous subunits of this complex are up-regulated in the lean perilipin 
null mouse, but not NDUFB5 or NDUFB6 in particular. We also observed a 1.7 fold 
decrease of C6orfl 07 in obese adipose tissue. The product of this gene is also thought to 
be involved in A TP coupled electron transport based on its proposed protein structure 
(http://genereg.oml.gov/gotm), but no mechanism has yet been elucidated. Furthermore, 
in obese individuals, we also observe a decrease of expression of ATP5S, which codes 
for the ATP synthase 5S subunit of the mitochondrial FO complex. It remains to be 
determined whether this reduction in the expression of genes involved electron transport 
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represent a primary effect leading to the obese state, or a secondary effect that results due 
to increased adiposity. 
Numerous other genes with functions in the mitochondria were also down-
regulated in obese individuals. Most of these genes code for transport proteins, such as 
solute carriers. It is difficult to determine what role, if any, these genes may play in the 
pathophysiology of obesity based on the current study, however many of the genes that 
have functions in the mitochondria were included in the cluster of genes we have used to 
distinguish between obese and non-obese individuals. These genes include the four genes 
mentioned earlier that are involved in A TP coupled electron transfer, as well as many of 
the mitochondrial transport proteins. This provides strong support to the theory that 
mitochondrial function and cellular energy production may play a role in the 
development of obesity. 
Previous studies have indicated that mitochondrial function and A TP generation 
may affect the rate of lipolysis (reviewed by Rossmeisl et al., 2004), and thus the status 
of adiposity in a given individual. The AMP activated protein kinase (AMPK) plays an 
important role in coupling cellular energy production to lipolysis. This enzyme responds 
to changes in the AMP/ATP ratio, and inhibits lipolysis in adipocytes (Winder et a/., 
1999). An increase in the AMP/ATP ratio (more AMP, less ATP), increases the activity 
of AMPK by promoting phosphorylation by an unknown AMPK kinase (Winder et a/., 
1999). Although we did not observe any differential expression with respect to this gene, 
we did observed a down regulation of two subunits of protein phosphatase 2A (PP2A) in 
obese individuals. PP2A is known to facilitate the interaction of regulatory and catalytic 
subunits of AMPK, thus keeping it in the inactive state (Gimeno-Alcaniz, et al., 2003). A 
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decrease in the expression of the genes encoding PP2A may represent a mechanism by 
which AMPK activity is increased in obese young men, thereby inhibiting lipolysis. 
Further work in this area could include an analysis of the ratio of inactive to active 
AMPK protein in lean and obese individuals, which could add credibility to this theory. 
Chapter 4.3: PKA induced lipolysis may be increased to compensate for excess 
adiposity in obese young men. 
We also detected a number of genes that are involved in the typical cAMP 
activated protein kinase (PKA) regulation of lipolysis, as differentially expressed in 
adipose tissue, including two regulatory subunits of PKA itself. One regulatory subunit 
(PRKAR2B), also know as RII-beta showed a decrease in obese subjects. Another 
regulatory subunit (PRKAR2A), also known as RII-alpha, showed an increase of 
expression in obese subjects. It is difficult to determine what affect this differential 
regulation has on the activity of PKA based on the current study, however it is possible 
that differential expression of regulatory subunit isoforms may change the enzymes 
activity. 
In support of this hypothesis, it has been shown that RII-beta knock out mice have 
a lean phenotype and are resistant to diet induced obesity (Planas et al., 1999). An 
absence of the RII-beta subunit can be compensated for by an increase in the expression 
of Rl-alpha, which more readily binds cAMP. This leads to lipolytic activation at lower 
levels of cAMP. Thus, these mice also exhibit an increase in the basal rate of lipolysis 
(Planas et al., 1999). We have shown a reduced expression ofRII-B in the adipose tissue 
of obese humans, and hypothesize that this indicates a compensatory mechanism of 
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lipolytic induction in response to increased adiposity. Support for this theory can also be 
gained through the use of animal models. For example, when RII-~ is deleted in the 
obese, leptin deficient ob/ob mouse, body weight is decreased and energy expenditure is 
increased (Newhall et al., 2005). This shows that knocking out RII- ~' or possibly 
decreasing its expression can counteract symptoms of obesity. The effect of increased 
RII-a expression is not as clear, as this subunit has not been implicated in the 
pathophysiology of obesity, and there is no data as to its ability to bind cAMP relative to 
other regulatory subunits. 
In addition, our results show the catalytic subunit of protein phosphatase 1 
(PPP1CA), has reduced expression in obese individuals. PPP1CA dephosphorylates 
perilipin (Clifford et al., 1998), a protein that protects the lipid droplet from lipolytic 
enzymes. Dephosphorylation of perilipin promotes association with the lipid droplet, and 
thus a decrease in PPP1CA would favor a situation whereby lipolysis is increased. A 
reduction in the expression of PPPlCA in obese individuals could also represent a 
secondary, or compensatory mechanism to increase the rate oflipolysis in the presence of 
increased adiposity. This gene is also a member of our 27 gene cluster, which adds 
further support for its role in the pathophysiology of obesity. 
In addition to PKA's direct role in lipolysis activation, this enzyme can also affect 
nuclear gene transcription, which can have numerous implications on energy balance and 
the development of obesity. PKA mainly affects gene transcription by phosphorlyation of 
the cyclic AMP response element binding protein (CREB) (Zhang et al., 2005). In animal 
models, loss of CREB function results in protection against diet induced obesity 
(Tsuchida et al., 2005). We have detected reduced expression of CREB 3-like-3 
53 
(CREB3L3), and the transducer of CREB (TORC2) in the adipose tissue of obese 
individuals. This down regulation of CREB may act as a compensatory mechanism to 
protect against further triglyceride accumulation in obese individuals, assuming that the 
function of CREB is conserved between mice and humans. 
Chapter 4.4: Numerous genes that may influence the rate of lipolysis. 
It has been well documented that insulin and insulin-like growth factor (IGF) 
signaling inhibits lipolysis through the cAMP/PKA pathway (Large et a/., 1998). We 
have identified GRB 10 as differentially expressed. GRB 10 is an adapter protein that 
serves to destabilize the insulin and the IGF receptors (Vecchione et a/., 2003). The 
expression of GRB 1 0 was reduced in obese individuals, which would favor a situation of 
increased insulin signaling, and therefore inhibition of lipolysis. Thus, this may represent 
a primary effect that may lead to increased adiposity. 
Recent evidence shows that the SIRT1 gene may play an important role in the 
pathophysiology of obesity. This gene has mainly been studied for its role in caloric 
restriction induced longevity, and is believed to interact with the insulin/IGF pathway in 
animal models (Tissenbaum et a/., 2001). However it is now known that SIRT1 can 
mobilize fat in white adipose tissue (Picard et a/., 2004), thereby providing a protective 
effect against obesity. We have detected a reduced expression of the SIRT1 gene in obese 
individuals. Moreover, this difference was highly significant (P = 0.00007). This would 
favor a situation of reduced fat mobilization in obese individuals. Thus the SIRT1 gene 
represents a good candidate for further work in the field of obesity. 
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In the present study, numerous other genes that may have important functions in 
the development of obesity were found to be differentially expressed between lean and 
obese individuals. One such gene is the nicotinic acid receptor, GPRl 09B, which we 
found to be down-regulated in obese adipose tissue. Nicotinic acid has been used for 
many years as an effective treatment for lowering serum lipid concentrations (Karpe et 
al., 2004), and is believed to affect the rate of lipolysis. However the mechanism is still 
poorly understood. As well, we detected an increased expression of the gene encoding the 
1-acylglycerol-3-phosphate 0-acyltransferase 4 protein (AGP AT4). Although there is 
very little data concerning the role of this gene in obesity, another gene of the same 
family (AGP A T2) has been implicated in a rare form of congenital lipodystrophy in 
humans. Loss of function mutations in this gene cause a complete absence of adipose 
tissue and susceptibility to type 2 diabetes (Gomes et al., 2004), but whether AGP AT4 
influences the state of obesity remains to be determined. 
Chapter 4.5: Summary of f"mdings 
In summary, we have identified 114 significantly up-regulated and 204 down-
regulated genes and transcripts in obese SCAT, when compared to non-obese SCAT. We 
have identified 181 genes that have never before been shown to be expressed in adipose 
tissue. This provides novel obesity candidate genes for further study. Furthermore, gene 
ontology analysis revealed an over-representation of genes involved in a specific range of 
biological process, which opens many new avenues for obesity related research. As well, 
we have discovered a set of 27 genes that accurately distinguishes between obese and 
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non-obese adipose tissue. The genes contained in this cluster all have ontology terms that 
are over-represented in our list of significantly differentially expressed genes, indicating 
potential roles for these genes, and the processes they are involved in the development of 
obesity. 
With respect to biological processes that are believed to be involved in the 
development and/or pathophysiology of obesity, our results indicate that ATP production 
within the SCAT mitochondria may be deregulated in obese young men, and that this 
may have implications on whole body energy balance. Furthermore, we detected 
numerous genes involved in the control of lipolysis as differentially expressed between 
obese and non-obese SCAT. The regulation patterns ofmost ofthese genes indicate that 
the rate of lipolysis may be increased in obese young men, possibly representing a 
secondary effect to compensate for increased adiposity. 
56 
Chapter 5: Future directions 
One of the main goals of the current work was to create a database of differential 
gene expression between obese and non-obese young men at baseline. The design of this 
study allows for further work involving adipose tissue gene expression profiles. Because 
mRNAs from the adipose tissue samples were competitively hybridized to our arrays 
with a standard reference RNA, we can now introduce nutritional challenges to our 
volunteers, and directly compare the results to the gene expression profiles at baseline. 
Moreover, any treatment can be introduced such as overfeeding, underfeeding, or acute 
exercise, and as long as the mRNAs from those adipose tissue samples are hybridized to 
an array with the same reference RNA, the results can be directly compared to baseline 
values. 
Furthermore, we have identified a set of genes that accurately distinguishes obese 
from non-obese young men. This cluster of genes can be tested in further work with a 
second, independent set of samples to ensure the legitimacy of this result. As well, this 
cluster can be tested in response to nutritional challenges, to determine if the set of 27 
genes can distinguish between the response to overfeeding, underfeeding, or acute 
exercise, in obese and non-obese individuals. 
The use of real time polymerase chain reaction would add an important 
experiment based on the current findings. This method could be used to quantify the 
levels of expression of any given gene, and could be used to verify a sub-set of our results 
from the microarray experiments. Specifically, the genes we identified that distinguish 
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between obese and non-obese should be tested to ensure that the regulation patterns we 
identified via microarray are indeed correct. 
One of the trends we identified in our data is that numerous genes with functions 
in the mitochondria, many of which are involved in the process of ATP coupled electron 
transport, have reduced expression in obese individuals. We hypothesize that AMPK may 
be involved in coupling reduced A TP production to the rate of lipolysis in adipose tissue. 
However this inference is based only on findings in other studies, and the fact that we 
identified an inhibitor of AMPK as having reduced expression in obese individuals. One 
crucial experiment that could clarify whether or not AMPK is involved in this process 
would be to measure the amount of AMPK protein, and activated AMPK protein 
(phosphorylated AMPK) via western blot. If AMPK is indeed involved in coupling A TP 
production to lipolysis in adipose tissue, one would expect increased levels of activated 
AMPK in obese adipose tissue, as AMPK is known to inhibit lipolysis (Winder et a/., 
1999) 
In addition, our lab is currently doing a large scale population based association 
study, where single nucleotide polymorphisms (SNPs) are genotyped and associated with 
measures of obesity and obesity related disorders. Previously, this study has focused on 
known obesity candidate genes known from the literature. As we have now identified 318 
genes that are differentially expressed between obese and non-obese adipose tissue, these 
genes can serve as obesity candidate genes for the association study. This will allow for 
the discovery of new obesity causative genes that have not been published elsewhere to 
date. 
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In summary, the current study has found many novel aspects of the genetic 
control of obesity, through the comparison of obese and non-obese expression profiles. 
Our results indicate a state of decreased expression of genes involved in A TP production. 
Our results also suggest that the process of lipolysis plays an important role in the 
pathophysiology of obesity. This process may be inhibited in obese individuals, but 
compensatory mechanisms such as a reduction in the expression of the R2-B regulatory 
subunit may act to increase TG hydrolysis in the presence of increased adiposity. 
Furthermore, we have defined a gene expression cluster that predicts the obese state with 
a high degree of accuracy. This cluster contains genes involved in lipolysis, as well as 
other biological processes that may also be involved in the development of obesity. Most 
importantly, the discovery of 181 novel obesity candidate genes provides valuable targets 
for further obesity and pharmaceutical based research. 
Although the current work adds much insight to the pathophysiology and etiology 
of obesity, there are limitations. Because the gene expression of adipose tissue was 
assayed at baseline, it is difficult to determine primary changes in gene expression as 
opposed to secondary changes in gene expression. That is, what changes are pathogenic, 
and may result in increased adiposity, and which changes are secondary due increased 
adiposity. In other words, for any change in expression for a given gene, it is difficult to 
determine if that change in a cause or an effect. Further work may help to distinguish 
between the two. One such experiment would be to assay the gene expression in adipose 
tissue in "pre-obese" individuals. "Pre-obese" individuals would be defined as people 
who are overweight, but not yet obese, and have a family history of obesity. This would 
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allow for a "snapshot" of a gene expression profile that may be primarily responsible for 
the development of obesity. 
In order to reduce the effect of confounding factors in the current work, we used 
male volunteers only, with a narrow age range. However this limits the interpretation of 
the results as the expression of genes that influence obesity, or any disease or condition, 
can be influenced by age and gender. This study will soon be repeated using female 
volunteers, and volunteers of an older age range to determine what genes may influence 
the status of adiposity in these subsets of the population, and how their profiles differ 
from those of young males. As well, due to the high cost of microarray studies, most 
work published to date involves a low sample number. We have used a total of 8 pairs, or 
16 individuals, in the current work. Although this is larger than most microarray studies 
conducted on adipose tissue, it is still relatively small and limits the statistical power of 
our study. 
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Appendix 1: CART gene association study 
The Cocaine-Amphetamine regulated transcript (CART) is a known obesity 
candidate gene. As part of the authors' thesis work, a population based association study 
was undertaken to determine if sequence variation in the CART gene is associated with 
obesity and/or obesity related phenotypes. As the number of subjects used in the study is 
small, and the study incomplete, a complete discussion of the material and results were 
not included in this thesis. Briefly, two single nucleotide polymorphisms located near the 
CART gene were genotyped in a total of 527 Newfoundlanders. These included an A/G 
SNP in the 5' untranslated region of the gene, and a CIT SNP in the 3' untranslated 
region of the gene. Fasting blood samples were taken for analysis of serum components 
and isolation of genomic DNA. Body composition was assayed using dual energy X-ray 
absorptiometry (DXA). The following represents primary data and basic statistical 
analysis for the CART gene association study. 
Results 
Physical characteristics of the subjects involved in the association study are 
shown in supplementary table 1. When analyzed by gender, men were significantly 
younger than women, and had a lower percentage of body fat. However, men had a 
significantly higher BMI when compared to women. Men were taller and heavier than 
women on average, and had higher serum levels of glucose. Women had significantly 
higher levels of serum HDL-C and TG. 
The frequency of the minor allele for the A/G SNP in the 5' region of the CART 
gene was 0.42. The frequency of the minor allele for the CIT SNP in the 3' region of the 
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CART gene was 0.15. Both SNP's were in Hardy-Weingberg equilibrium as assessed by 
Chi-squared analysis. As little difference between genders was observed with the 
associations, analysis of allele and genotype associations are reported in all volunteers 
combined unless otherwise stated. 
As shown in supplementary table 2, no significant differences were seen 
between physical and biochemical characteristics and the three possible genotypes for the 
5' NGSNP. 
Similarly, as shown in supplementary table 3, no differences were seen between 
the three genotypes for the 3' CIT SNP and measures of obesity, however minor allele 
homozygotes do have significantly lower levels of fasting serum insulin. However, 
fasting levels of glucose remain normal, as is the measure of insulin resistance (BOMA-
R), so the biological significance of this trend remains unclear. 
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Supplementary table 1: Physical and biochemical characteristics of the subjects for 
CART gene association analysis. 
Characteristic All subjects Women men 
(n=527) (n=409) (n=118) 
Age 42.18 (19-62) 42.7 (19-62) 39.8 (19-61)* 
%BF 34.69 (4.6-59.9) 36.7 (4.6-59.9) 24.6 (7.4-41.6)* 
BMI 26.21 (16.98-54.27) 26.0 (17.0-54.3) 27.4 (19.9-43.3)* 
Height 164.3- (134-198) 162.1 (135-178) 175.0 (157-198)* 
Weight 70.87 (45.4-156.8) 68.1 (45.4-156.8) 83.7 (54.7-136.5)* 
Insulin 72.8 (15.7-720.0) 72.3 (15.7- 720) 75.5 (22.9-301.0) 
Glucose 5.1 (2.2- 7.0) 5.0 (3.0-10.8) 5.3 (2.2-14.4)* 
HDL-C 1.52 (0.65-3.15) 1.59 (0.79-3.15) 1.24 (0.65-2.21 )* 
LDL-C 3.17 (1.02-7.61) 3.18 (1.02-7.16) 3.14 (1.31-5.69) 
TG 1.28 (0.27 -5.88) 1.50 (0.31-4. 7) 1.23 (0.27-5.88)* 
HOMA-R 2.4 (0.5-22.8) 2.3 (0.5-22.8) 2.5 (0.5-1 0.6) 
Data presented as mean, (range in parentheses) 
*indicates statistically significant difference between males and females, student t-test 
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Supplementary table 2: Genotypic association between the S' AJG SNP and 
measures of obesity and related phenotypes. 
Characteristic minor allele heterozygotes major allele 
homozygotes homozygotes 
N 99 226 157 
%Body Fat 35.0 ± 8.6 34.8 ± 9.1 34.0± 8.4 
BMI 26.2 ± 5.3 26.4 ± 5.3 26.3 ± 4.6 
Glucose 5.17 ± 1.33 5.11 ± 0.79 4.98 ± 0.51 
Insulin1 74.8 ± 45.3 73.7 ± 60.5 73.6 ± 43.3 
HDL 1.53 ± 0.35 1.52 ± 0.33 1.54 ± 0.42 
LDL 3.17±0.77 3.22 ±0.90 3.17 ± 0.84 
TG1 1.32 ± 0.88 1.29 ± 0.83 1.24 ± 0.79 
HOMA-R1 2.44 ± 1.83 2.34 ± 1.70 2.41 ± 2.20 
Data presented as mean ± SD 
No significant differences, as assessed by one-factor ANOVA, corrected for multiple 
testing using Bonferroni t-test. 
1transformed using the natural Log for significance testing 
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Supplementary table 3: Genotypic associations between the 3' Cff SNP and 
measures of obesity and related phenotypes. 
Characteristic minor allele heterozygotes major allele 
Homozygotes heterozygotes 
N 13-14 137-158 375-444 
%Body Fat 35.4 ± 7.6 34.7 ± 9.3 34.6± 8.7 
BMI 26.8 ± 7.2 26.3 ±4.8 26.1 ±4.9 
Glucose 4.9 ± 0.4 5.0 ±0.9 5.1 ± 0.8 
Insulin1 46.3 ± 21.4* 69.8 ±45.4 74.9 ± 53.7 
HDL 1.44 ± 0.26 1.56 ± 0.40 1.53 ± 0.38 
LDL 3.27 ± 0.66 3.21 ± 0.87 3.17 ± 0.86 
1.07 ± 0.60 1.25 ± 0.90 1.30 ± 0.81 
HOMA-R1 2.16 ± 1.20 2.30 ± 1.66 2.39 ± 1.97 
Data presented as mean ± SD 
*significant from all other genotypes, p S 0.01, one-factor ANOVA 
1transformed using the natural Log for significance testing 
70 
Appendix 2: Published manuscript 
As part of my graduate project, I also collected data for another study, which 
assessed the differences between two methods of body fat estimation. For this study, we 
compared body fat estimation by bioelectrical impedance analysis (BIA) to that of a 
standard method, dual energy X-ray abosrptiometry (DXA). The main finding of this 
study was that the bias introduced by BIA is dependant on the adiposity of the individual. 
This study was published in the American Journal of Clinical nutrition, of which the 
abstract is presented below. As the second author, I was responsible for data collection, 
statistical analysis, and editing the manuscript. 
Abstract 
Background: Bioimpedance analysis (BIA) is widely used in clinics and research work 
to measure body composition. However the results of BIA validation with reference 
methods are contradictive, and there is little data about the influence of adiposity on 
measurement of body composition by BIA. 
Objective: To determine the effect of gender and adiposity on the validity of BIA 
predicted %Fat when compared to that of dual energy X-ray absorptiometry (DXA). 
Design: 591 healthy subjects were recruited in Newfoundland and Labrador. %Fat was 
predicted using BIA and compared to dual energy X-ray absorptiometry. Methods 
agreement was assessed by Pearson correlation, and Bland and Altman analysis. 
Differences of percent body fat among groups based on gender and adiposity was 
performed using one-way ANOV A and corrected using Bonferroni. 
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Results: Correlation between BIA and DXA reaches 0.88 for the whole population, 0.78 
for men, and 0.85 for women. The mean %Fat determined by BIA (32.89 ± 8.0) was 
significantly lower than that by DXA (34.72 ± 8.70). BIA significantly overestimated 
%Fat in lean subjects and underestimated %Fat in overweight subjects. The cutoffs are 
gender specific. BIA overestimated by 3.0% and 4.4 % when %Fat is <15 in men and 
<25 in women, and underestimated by 4.3% and 2.7% when %Fat> 25 in men and >33 
in women. 
Conclusions: BIA is a good alternative to estimate percent body fat when subjects are 
within a healthy range of %Fat. BIA tends to overestimate %Fat for lean subjects and 
underestimate %Fat in obese subjects. 
(American Journal of Clinical Nutrition, 81 (1): 74-79.) 
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